The Wegovy slimming jab: what you should know before you start

What does the Wegovy jab actually do inside the body?

Semaglutide belongs to a class called GLP-1 receptor agonists. GLP-1 is a hormone your gut releases after eating; it signals satiety to the brain, slows the rate at which your stomach empties, and plays a role in regulating blood sugar. Wegovy is a synthetic version of that hormone, engineered to last a full week in the body after a single injection.

The practical effect for most people is a noticeable reduction in appetite and a lower tolerance for large portions — food simply becomes less compelling. That's not willpower; it's pharmacology. One misconception worth clearing up gently: the injection doesn't burn fat directly or speed up metabolism in a meaningful way. It reduces the drive to eat. The weight loss that follows comes from a sustained calorie deficit that feels, for many, far less effortful than dieting alone.

The semaglutide overview on this site covers the mechanism in more detail if you'd like to go deeper. The NHS medicines information for semaglutide is also a useful reference for the clinical picture, available at nhs.uk/medicines/semaglutide.

What does the trial evidence say about results?

The headline figure comes from the STEP 1 trial: adults with obesity who used semaglutide 2.4mg alongside lifestyle changes lost an average of around 15% of their body weight over 68 weeks, compared with roughly 2.4% in the placebo group. Those figures are from a randomised controlled trial published in the New England Journal of Medicine (STEP 1, 2021) and remain the most-cited evidence for the standard maintenance dose.

Since then, Novo Nordisk developed a higher 7.2mg dose. Trials at that level reported average weight loss of around 20.7% over 72 weeks, approaching results seen with tirzepatide at its highest dose. The MHRA approved the dedicated single-dose 7.2mg pen in April 2026; it's designed for one injection per week with a built-in covered needle. The starting dose and titration schedule remain the same regardless of which maintenance dose you eventually reach.

Results vary. Genetics, starting weight, lifestyle changes and how long someone stays on treatment all affect the outcome. Clinical trials show what happens on average across large groups; your individual experience is something a prescriber works through with you over time. You can read a fuller comparison of the Wegovy weight-loss injection and what patients typically experience on our dedicated page.

Who is the Wegovy slimming jab suitable for?

The UK licence sets two eligibility thresholds: a BMI of 30 or above, or a BMI of 27 to 29.9 if you have at least one weight-related condition, such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance, typically 2.5 kg/m² below the standard figures.

Several groups should not use Wegovy. It isn't licensed for anyone under 18. It isn't recommended during pregnancy, while breastfeeding, or for people who are trying to conceive. A personal or family history of medullary thyroid carcinoma or MEN2 syndrome requires a careful prescriber conversation before any GLP-1 medicine is considered.

On the NHS, access via NICE's guidance (TA875) is limited to specialist weight management services and specific clinical criteria, waiting lists can be long, and not everyone who is eligible on paper will meet the full referral threshold. Private treatment through a regulated pharmacy is the alternative route for people who don't qualify for NHS provision or prefer not to wait. For a clear look at what Wegovy costs privately, that page sets out what a legitimate price should include. On the weight-loss treatments overview you can also see how Wegovy sits alongside other licensed options.

What are the most common side effects to know about?

The side-effect profile is dominated by gastrointestinal symptoms: nausea, vomiting, diarrhoea, constipation, indigestion and burping are all reported more often than with placebo. For most people these are most noticeable after starting treatment or after a dose increase, and they tend to settle within a few days to two weeks as the body adjusts. If you want background on how the slimming drug Wegovy came to be licensed and what sets it apart from earlier treatments, that page gives a useful overview. The slow titration schedule (moving up through doses only when your system has had time to settle) exists specifically to reduce how disruptive this period is.

Less common but more serious reactions include acute pancreatitis, which the MHRA highlighted in a safety communication in early 2026. Seek urgent medical help for severe, persistent stomach pain that spreads to the back, with or without vomiting. Gallbladder problems are also associated with rapid weight loss in general and have been reported with semaglutide, and our page on the fat jab semaglutide explains how the active ingredient works across different branded products. Allergic reactions, though rare, require immediate attention.

If you experience something you're not sure about, the MHRA Yellow Card scheme lets you report suspected side effects directly. Any question about whether a symptom is related to your treatment should go to your prescriber rather than waiting it out. Our FAQs include common questions about managing the first few weeks, and the Wegovy injection guide covers practical points like injection technique and rotating sites. If you'd like to talk through whether this treatment suits your situation, checking your eligibility with our prescribers is the place to start.